Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 15;131(20):e154889.
doi: 10.1172/JCI154889.

Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside

Erik S Musiek  1 , Teresa Gomez-Isla  2   3 , David M Holtzman  1
Affiliations

Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside

Erik S Musiek et al. J Clin Invest. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: ESM has consulted with and received research funding related to sleep research from Eisai Pharmaceuticals. TGI participated as speaker in a Lilly-sponsored educational symposium and serves as member of a Lilly Data Monitoring Committee. DMH is listed as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies (US patent 9,834,596). DMH cofounded and is on the scientific advisory board of C2N Diagnostics, which has licensed certain anti-tau antibodies to AbbVie for therapeutic development. DMH is an inventor on patents for a humanized anti-Aβ antibody “Humanized antibodies that sequester amyloid beta peptide” (US patents 7,195,761 and 7,892,545) licensed to Eli Lilly. DMH is on the scientific advisory boards of Denali and Genentech and consults for Cajal Neuroscience, Takeda, and Eli Lilly.

References

    1. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nat Neurosci. 2015;18(6):800–806. doi: 10.1038/nn.4018. - DOI - PMC - PubMed
    1. Donohue MC, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317(22):2305–2316. doi: 10.1001/jama.2017.6669. - DOI - PMC - PubMed
    1. Jack CR, Jr, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–562. doi: 10.1016/j.jalz.2018.02.018. - DOI - PMC - PubMed
    1. Arriagada PV, et al. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurology. 1992;42(9):1681–1688. doi: 10.1212/WNL.42.9.1681. - DOI - PubMed
    1. Gómez-Isla T, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol. 1997;41(1):17–24. doi: 10.1002/ana.410410106. - DOI - PubMed

MeSH terms